drugset / Trial / NCT05962151
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
RandomizedCrossoverDouble-blindTreatment
Summary
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2025-01-06
- Completion
- 2025-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | 27 mg | Oral |
| Subject | Nalbuphine | Small molecule | 54 mg | Oral |
| Subject | Nalbuphine | Small molecule | 108 mg | Oral |